AU2015239100B2 - Macrocylic pyridine derivatives - Google Patents
Macrocylic pyridine derivatives Download PDFInfo
- Publication number
- AU2015239100B2 AU2015239100B2 AU2015239100A AU2015239100A AU2015239100B2 AU 2015239100 B2 AU2015239100 B2 AU 2015239100B2 AU 2015239100 A AU2015239100 A AU 2015239100A AU 2015239100 A AU2015239100 A AU 2015239100A AU 2015239100 B2 AU2015239100 B2 AU 2015239100B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- 4alkyl
- int
- independently
- hydroxyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CC[C@]1C(**2)C2CC1 Chemical compound CC[C@]1C(**2)C2CC1 0.000 description 9
- XVEORPPYZDDVTA-UHFFFAOYSA-N CC(c1cccc(Nc2cc(-c3cnc(NCCCN4)nc3)ccn2)c1F)N(CC1)CCN1C1(CC1)C4=O Chemical compound CC(c1cccc(Nc2cc(-c3cnc(NCCCN4)nc3)ccn2)c1F)N(CC1)CCN1C1(CC1)C4=O XVEORPPYZDDVTA-UHFFFAOYSA-N 0.000 description 2
- HVKSMDQLKOBQIN-UHFFFAOYSA-N O=C(CN1CCNCC1)NCCC1NCCC1 Chemical compound O=C(CN1CCNCC1)NCCC1NCCC1 HVKSMDQLKOBQIN-UHFFFAOYSA-N 0.000 description 2
- PDKHDWLWDFKJLJ-SOFGYWHQSA-N CC(/C=C/Nc1nccc(-c2ccc(C)nc2)c1)=C Chemical compound CC(/C=C/Nc1nccc(-c2ccc(C)nc2)c1)=C PDKHDWLWDFKJLJ-SOFGYWHQSA-N 0.000 description 1
- HAIKRMHUOLXNQZ-UHFFFAOYSA-N CC(C)(C)OC(CN(C1)CC1Oc1cc([N+](O)=O)ccc1)=O Chemical compound CC(C)(C)OC(CN(C1)CC1Oc1cc([N+](O)=O)ccc1)=O HAIKRMHUOLXNQZ-UHFFFAOYSA-N 0.000 description 1
- WOZHBWOXBDBWGU-UHFFFAOYSA-O CC(C)(C)OC(CN(CC1)CCC1Oc1cc([NH+]=C)ccc1)=O Chemical compound CC(C)(C)OC(CN(CC1)CCC1Oc1cc([NH+]=C)ccc1)=O WOZHBWOXBDBWGU-UHFFFAOYSA-O 0.000 description 1
- AQGCFXLNLXYORA-UHFFFAOYSA-N CC(C)(C)OC(CN1CC(CO)N(Cc2cc(N)ccc2)CC1)=O Chemical compound CC(C)(C)OC(CN1CC(CO)N(Cc2cc(N)ccc2)CC1)=O AQGCFXLNLXYORA-UHFFFAOYSA-N 0.000 description 1
- NIVOLJPAAFLSKP-UHFFFAOYSA-N CC(C)(C)OC(CN1CC(CO)N(Cc2cc([N+](O)=O)ccc2)CC1)=O Chemical compound CC(C)(C)OC(CN1CC(CO)N(Cc2cc([N+](O)=O)ccc2)CC1)=O NIVOLJPAAFLSKP-UHFFFAOYSA-N 0.000 description 1
- KXZKCZDADWBDEV-UHFFFAOYSA-N CC(C)(C)OC(CN1CC(COCCC#N)N(Cc2ccccc2)CC1)=O Chemical compound CC(C)(C)OC(CN1CC(COCCC#N)N(Cc2ccccc2)CC1)=O KXZKCZDADWBDEV-UHFFFAOYSA-N 0.000 description 1
- DQSKZTUVIVRCEE-UHFFFAOYSA-N CC(C)(C)OC(CN1CCN(Cc(cc(C)cc2)c2C(OC)=O)CC1)=O Chemical compound CC(C)(C)OC(CN1CCN(Cc(cc(C)cc2)c2C(OC)=O)CC1)=O DQSKZTUVIVRCEE-UHFFFAOYSA-N 0.000 description 1
- LOLAOYYFWVSXSX-UHFFFAOYSA-N CC(C)(C)OC(CN1CCN(Cc2cc(Nc3cc(-c4cnc(N(C5)C(CCN)CC5O[Si](C)(C)C(C)(C)C)nc4)ccn3)ccc2F)CC1)=O Chemical compound CC(C)(C)OC(CN1CCN(Cc2cc(Nc3cc(-c4cnc(N(C5)C(CCN)CC5O[Si](C)(C)C(C)(C)C)nc4)ccn3)ccc2F)CC1)=O LOLAOYYFWVSXSX-UHFFFAOYSA-N 0.000 description 1
- TWGLMOMSGGNCIZ-UHFFFAOYSA-N CC(C)(C)OC(CN1CCN(Cc2cc(Nc3nccc(-c4cnc(NC(CCNC(OC(C)(C)C)=O)C(OC)=O)nc4)c3)ccc2)CC1)=O Chemical compound CC(C)(C)OC(CN1CCN(Cc2cc(Nc3nccc(-c4cnc(NC(CCNC(OC(C)(C)C)=O)C(OC)=O)nc4)c3)ccc2)CC1)=O TWGLMOMSGGNCIZ-UHFFFAOYSA-N 0.000 description 1
- DXGSERVSIIVHHT-UHFFFAOYSA-N CC(C)(C)OC(CN1CCN(Cc2cccc(Nc3cc(-c4cnc(CNCCNC(OC(C)(C)C)=O)nc4)ccn3)c2)CC1)=C Chemical compound CC(C)(C)OC(CN1CCN(Cc2cccc(Nc3cc(-c4cnc(CNCCNC(OC(C)(C)C)=O)nc4)ccn3)c2)CC1)=C DXGSERVSIIVHHT-UHFFFAOYSA-N 0.000 description 1
- VHIUAMWORWIWOJ-UHFFFAOYSA-N CC(C)(C)OC(CN1CCN(Cc2cccc(Nc3nccc(-c4cnc(CN(CCNC(OC(C)(C)C)=O)C(OC(C)(C)C)=O)nc4)c3)c2)CC1)=O Chemical compound CC(C)(C)OC(CN1CCN(Cc2cccc(Nc3nccc(-c4cnc(CN(CCNC(OC(C)(C)C)=O)C(OC(C)(C)C)=O)nc4)c3)c2)CC1)=O VHIUAMWORWIWOJ-UHFFFAOYSA-N 0.000 description 1
- GJQYEWUVXPELPQ-UHFFFAOYSA-N CC(C)(C)OC(N(C)CCCNc(nc1)ncc1Br)=O Chemical compound CC(C)(C)OC(N(C)CCCNc(nc1)ncc1Br)=O GJQYEWUVXPELPQ-UHFFFAOYSA-N 0.000 description 1
- RADJPWCJEYOQAX-UHFFFAOYSA-N CC(C)(C)OC(N(C)CCNc1ncc(C)cn1)=O Chemical compound CC(C)(C)OC(N(C)CCNc1ncc(C)cn1)=O RADJPWCJEYOQAX-UHFFFAOYSA-N 0.000 description 1
- MTGPFMRINJXGJC-UHFFFAOYSA-N CC(C)(C)OC(NCCCNc(cc1)ncc1-c1cc(Nc2cc(CO)ccc2)ncc1)=O Chemical compound CC(C)(C)OC(NCCCNc(cc1)ncc1-c1cc(Nc2cc(CO)ccc2)ncc1)=O MTGPFMRINJXGJC-UHFFFAOYSA-N 0.000 description 1
- NSSTWMBLNISSMB-UHFFFAOYSA-N CC(C)(C)OC(NCCCNc(cc1)nnc1-c1ccnc(F)c1)=O Chemical compound CC(C)(C)OC(NCCCNc(cc1)nnc1-c1ccnc(F)c1)=O NSSTWMBLNISSMB-UHFFFAOYSA-N 0.000 description 1
- SNDSJRNFOOMDBR-UHFFFAOYSA-N CC(C)(C)OC(NCCN(CCC1)C1c(nc1)ncc1I)=O Chemical compound CC(C)(C)OC(NCCN(CCC1)C1c(nc1)ncc1I)=O SNDSJRNFOOMDBR-UHFFFAOYSA-N 0.000 description 1
- BOGIIXAMOVPKHD-UHFFFAOYSA-N CC(C)(C)[Si+](C)(C)OC(CC1CC#N)CN1c(nc1)ncc1-c1ccnc(Nc2cc(N(C)C(CC3)CCN3C3(CC3)C(OC)=O)ccc2)c1 Chemical compound CC(C)(C)[Si+](C)(C)OC(CC1CC#N)CN1c(nc1)ncc1-c1ccnc(Nc2cc(N(C)C(CC3)CCN3C3(CC3)C(OC)=O)ccc2)c1 BOGIIXAMOVPKHD-UHFFFAOYSA-N 0.000 description 1
- JHMHAQUKEZXKFO-UHFFFAOYSA-N CC(CN1CCN(Cc2cccc(Nc3nccc(-c4cnc(NC(CCN)CC5CC5)nc4)c3)c2)CC1)=O Chemical compound CC(CN1CCN(Cc2cccc(Nc3nccc(-c4cnc(NC(CCN)CC5CC5)nc4)c3)c2)CC1)=O JHMHAQUKEZXKFO-UHFFFAOYSA-N 0.000 description 1
- XCXSOHJTLJLBHV-UHFFFAOYSA-N CC(NCCCCC(C(O)=O)N1CCN(Cc2cc(Nc3cc(-c4cnc(NCCCN)nc4)ccn3)ccc2)CC1)=O Chemical compound CC(NCCCCC(C(O)=O)N1CCN(Cc2cc(Nc3cc(-c4cnc(NCCCN)nc4)ccn3)ccc2)CC1)=O XCXSOHJTLJLBHV-UHFFFAOYSA-N 0.000 description 1
- JSRIGJCJKRTIKP-UHFFFAOYSA-N CC(c(cccc1Nc2cc(-c3cnc(N(C4)C(CCN)CC4O)nc3)ccn2)c1F)N(CC1)CCN1C1(CC1)C(O)=O Chemical compound CC(c(cccc1Nc2cc(-c3cnc(N(C4)C(CCN)CC4O)nc3)ccn2)c1F)N(CC1)CCN1C1(CC1)C(O)=O JSRIGJCJKRTIKP-UHFFFAOYSA-N 0.000 description 1
- ZLPBJHWEQFHSLB-UHFFFAOYSA-N CC(c(cccc1Nc2nccc(-c3cnc(NCCCN)nc3)c2)c1F)N(CC1)CCN1C1(CC1)C(C)=O Chemical compound CC(c(cccc1Nc2nccc(-c3cnc(NCCCN)nc3)c2)c1F)N(CC1)CCN1C1(CC1)C(C)=O ZLPBJHWEQFHSLB-UHFFFAOYSA-N 0.000 description 1
- DUSFGQMCUNCOJP-UHFFFAOYSA-N CC1N(C)CC=C1 Chemical compound CC1N(C)CC=C1 DUSFGQMCUNCOJP-UHFFFAOYSA-N 0.000 description 1
- RCVVUEXAHZOTJZ-UHFFFAOYSA-N CC1N(Cc2cc(Nc3nccc(-c4cnc(NCCCN)nc4)c3)ccc2)C(C)CN(CC(O)=O)C1 Chemical compound CC1N(Cc2cc(Nc3nccc(-c4cnc(NCCCN)nc4)c3)ccc2)C(C)CN(CC(O)=O)C1 RCVVUEXAHZOTJZ-UHFFFAOYSA-N 0.000 description 1
- RQDHRFNLDJXATA-UHFFFAOYSA-N CCCN(CCNC(CN(CC1)CCN1Cc1cc(N2)ccc1)=O)Cc(nc1)ncc1-c1ccnc2c1 Chemical compound CCCN(CCNC(CN(CC1)CCN1Cc1cc(N2)ccc1)=O)Cc(nc1)ncc1-c1ccnc2c1 RQDHRFNLDJXATA-UHFFFAOYSA-N 0.000 description 1
- GXHUUROPVFBGNH-UHFFFAOYSA-N CNCCCNc(nc1)ccc1-c1ccnc(Nc2cccc(CN3CCN(CC(O)=O)CC3)c2)c1 Chemical compound CNCCCNc(nc1)ccc1-c1ccnc(Nc2cccc(CN3CCN(CC(O)=O)CC3)c2)c1 GXHUUROPVFBGNH-UHFFFAOYSA-N 0.000 description 1
- JETBMNOPXHXITF-UHFFFAOYSA-N COCC(C(OC)=O)N1CCN(Cc2cccc(N=O)c2)CC1 Chemical compound COCC(C(OC)=O)N1CCN(Cc2cccc(N=O)c2)CC1 JETBMNOPXHXITF-UHFFFAOYSA-N 0.000 description 1
- OWVOCJSLZIUTJT-UHFFFAOYSA-N CS(OCc(nc1)ncc1Br)(=O)=O Chemical compound CS(OCc(nc1)ncc1Br)(=O)=O OWVOCJSLZIUTJT-UHFFFAOYSA-N 0.000 description 1
- WRVVPCRKKFIHSK-UHFFFAOYSA-N Fc(c(OC1CCNCC1)ccc1)c1Nc1nccc(-c2cnc(NI)nc2)c1 Chemical compound Fc(c(OC1CCNCC1)ccc1)c1Nc1nccc(-c2cnc(NI)nc2)c1 WRVVPCRKKFIHSK-UHFFFAOYSA-N 0.000 description 1
- BOLIPIINZJGLFM-UHFFFAOYSA-N N#CCCOCC1N(Cc2ccccc2)CCNC1 Chemical compound N#CCCOCC1N(Cc2ccccc2)CCNC1 BOLIPIINZJGLFM-UHFFFAOYSA-N 0.000 description 1
- FSOOAJOFRONUMR-UHFFFAOYSA-N NCCCNc(nc1)ncc1-c1cc(Nc2cc(CN3CC(CC4)N(CC(O)=O)C4C3)ccc2)ncc1 Chemical compound NCCCNc(nc1)ncc1-c1cc(Nc2cc(CN3CC(CC4)N(CC(O)=O)C4C3)ccc2)ncc1 FSOOAJOFRONUMR-UHFFFAOYSA-N 0.000 description 1
- DNRJAQQJBAGWNW-UHFFFAOYSA-N NCCCNc(nc1)ncc1-c1ccnc(Nc(cccc2OC3CCN(CC(O)=O)CC3)c2F)c1 Chemical compound NCCCNc(nc1)ncc1-c1ccnc(Nc(cccc2OC3CCN(CC(O)=O)CC3)c2F)c1 DNRJAQQJBAGWNW-UHFFFAOYSA-N 0.000 description 1
- NTNHYWHXHDBMJU-UHFFFAOYSA-N NCCCNc(nc1)ncc1-c1ccnc(Nc2cc(CN3C(COCCC#N)CN(CC(O)=O)CC3)ccc2)c1 Chemical compound NCCCNc(nc1)ncc1-c1ccnc(Nc2cc(CN3C(COCCC#N)CN(CC(O)=O)CC3)ccc2)c1 NTNHYWHXHDBMJU-UHFFFAOYSA-N 0.000 description 1
- XJEONFHDWZZIFV-UHFFFAOYSA-N O=C(CN1C(CC2)CN(Cc3cccc(N4)c3)C2C1)NCCCNc(nc1)ncc1-c1cc4ncc1 Chemical compound O=C(CN1C(CC2)CN(Cc3cccc(N4)c3)C2C1)NCCCNc(nc1)ncc1-c1cc4ncc1 XJEONFHDWZZIFV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14163442.8 | 2014-04-03 | ||
| EP14163442 | 2014-04-03 | ||
| EP14183823 | 2014-09-05 | ||
| EP14183823.5 | 2014-09-05 | ||
| PCT/EP2015/057401 WO2015150557A1 (en) | 2014-04-03 | 2015-04-02 | Macrocylic pyridine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015239100A1 AU2015239100A1 (en) | 2016-09-29 |
| AU2015239100B2 true AU2015239100B2 (en) | 2019-06-27 |
Family
ID=52781118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015239100A Ceased AU2015239100B2 (en) | 2014-04-03 | 2015-04-02 | Macrocylic pyridine derivatives |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20170022201A1 (enExample) |
| EP (1) | EP3126365B1 (enExample) |
| JP (1) | JP6420362B2 (enExample) |
| KR (1) | KR102390274B1 (enExample) |
| CN (1) | CN106132964B (enExample) |
| AU (1) | AU2015239100B2 (enExample) |
| BR (1) | BR112016022700B1 (enExample) |
| CA (1) | CA2942751C (enExample) |
| CL (1) | CL2016002495A1 (enExample) |
| EA (1) | EA029758B1 (enExample) |
| ES (1) | ES2665797T3 (enExample) |
| IL (1) | IL248001B (enExample) |
| MA (1) | MA39823A (enExample) |
| MX (1) | MX369799B (enExample) |
| MY (1) | MY185500A (enExample) |
| NZ (1) | NZ725406A (enExample) |
| PE (1) | PE20161365A1 (enExample) |
| PH (1) | PH12016501962B1 (enExample) |
| SG (1) | SG11201608241UA (enExample) |
| UA (1) | UA118120C2 (enExample) |
| WO (1) | WO2015150557A1 (enExample) |
| ZA (1) | ZA201606768B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10407442B2 (en) | 2015-09-24 | 2019-09-10 | Cyclenium Pharma Inc. | Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same |
| AU2017219846B2 (en) | 2016-02-19 | 2021-05-13 | Sprint Bioscience Ab | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes |
| LT3416957T (lt) | 2016-02-19 | 2020-11-25 | Sprint Bioscience Ab | 6-heterociklil-4-morfolin-4-ilpiridin-2-ono junginiai, tinkami vėžio ir diabeto gydymui |
| IL316954A (en) | 2017-02-28 | 2025-01-01 | Morphic Therapeutic Inc | (Alpha-V)(beta-6)integrin inhibitors |
| EP3760202A1 (en) | 2017-02-28 | 2021-01-06 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| ES2900199T3 (es) | 2017-03-28 | 2022-03-16 | Bayer Ag | Novedosos compuestos macrocíclicos inhibidores de PTEFB |
| WO2018177889A1 (en) | 2017-03-28 | 2018-10-04 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
| US20200190083A1 (en) * | 2017-06-22 | 2020-06-18 | Cyclenium Pharma Inc. | Libraries of pyridine-containing macrocyclic compounds and methods of making and using the same |
| CN116589461A (zh) | 2017-08-23 | 2023-08-15 | 思普瑞特生物科学公司 | 氮杂吲哚基吡啶酮化合物和二氮杂吲哚基吡啶酮化合物 |
| IL302293A (en) | 2017-08-23 | 2023-06-01 | Sprint Bioscience Ab | Pyridinamine-pyridone and pyrimidinamine-pyridone compounds |
| IL302077A (en) | 2017-08-23 | 2023-06-01 | Sprint Bioscience Ab | Morpholinylpyridone compounds |
| EP4056556A1 (en) | 2017-08-23 | 2022-09-14 | Sprint Bioscience AB | Pyridylpyridone compounds |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| UY38352A (es) | 2018-08-29 | 2020-03-31 | Morphic Therapeutic Inc | Inhibidores de integrina alfavbeta6 |
| UY38353A (es) | 2018-08-29 | 2020-03-31 | Morphic Therapeutic Inc | Inhibición de integrina alfavbeta6 |
| EP4013762A1 (en) * | 2019-08-16 | 2022-06-22 | Inflazome Limited | Macrocyclic sulfonylamide derivatives useful as nlrp3 inhibitors |
| CN113845521B (zh) * | 2021-08-31 | 2024-06-18 | 中原工学院 | 水相中光催化一锅法合成咪唑并含氮杂环肼类衍生物的方法 |
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009112439A1 (en) * | 2008-03-10 | 2009-09-17 | Janssen Pharmaceutica Nv | 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001051125A1 (en) * | 2000-01-12 | 2001-07-19 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| WO2004078682A2 (en) * | 2003-03-05 | 2004-09-16 | Irm Llc | Cyclic compounds and compositions as protein kinase inhibitors |
| PA8603801A1 (es) | 2003-05-27 | 2004-12-16 | Janssen Pharmaceutica Nv | Derivados de la quinazolina |
| EP1697384B1 (en) | 2003-12-18 | 2008-04-02 | Janssen Pharmaceutica N.V. | Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents |
| ES2335216T3 (es) | 2003-12-18 | 2010-03-23 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-quinolina con actividad antiproliferativa. |
| MY169441A (en) | 2004-12-08 | 2019-04-11 | Janssen Pharmaceutica Nv | 2,4, (4,6) pyrimidine derivatives |
| JO3088B1 (ar) | 2004-12-08 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف |
| US8778919B2 (en) * | 2005-06-30 | 2014-07-15 | Janssen Pharmaceutica Nv | Cyclic anilino—pyridinotriazines |
| EP1951729B1 (en) * | 2005-11-16 | 2014-06-25 | Cell Therapeutics, Inc. | Oxygen linked pyrimidine derivatives |
| CA2687909C (en) | 2007-06-21 | 2015-09-15 | Janssen Pharmaceutica Nv | Indolin-2-ones and aza-indolin-2-ones |
| US8318731B2 (en) | 2007-07-27 | 2012-11-27 | Janssen Pharmaceutica Nv | Pyrrolopyrimidines |
| KR20110031318A (ko) | 2008-06-13 | 2011-03-25 | 노파르티스 아게 | Ｉａ 심부전 및 암 치료에 유용한 단백질 키나제 ｄ 억제제로서의 2,4'-비피리디닐 화합물 |
-
2015
- 2015-04-01 MA MA039823A patent/MA39823A/fr unknown
- 2015-04-02 NZ NZ725406A patent/NZ725406A/en not_active IP Right Cessation
- 2015-04-02 EA EA201692000A patent/EA029758B1/ru not_active IP Right Cessation
- 2015-04-02 MY MYPI2016001776A patent/MY185500A/en unknown
- 2015-04-02 ES ES15713523.7T patent/ES2665797T3/es active Active
- 2015-04-02 SG SG11201608241UA patent/SG11201608241UA/en unknown
- 2015-04-02 WO PCT/EP2015/057401 patent/WO2015150557A1/en not_active Ceased
- 2015-04-02 EP EP15713523.7A patent/EP3126365B1/en active Active
- 2015-04-02 BR BR112016022700-0A patent/BR112016022700B1/pt not_active IP Right Cessation
- 2015-04-02 UA UAA201611003A patent/UA118120C2/uk unknown
- 2015-04-02 AU AU2015239100A patent/AU2015239100B2/en not_active Ceased
- 2015-04-02 CN CN201580018081.0A patent/CN106132964B/zh active Active
- 2015-04-02 JP JP2016560816A patent/JP6420362B2/ja active Active
- 2015-04-02 PE PE2016001843A patent/PE20161365A1/es active IP Right Grant
- 2015-04-02 CA CA2942751A patent/CA2942751C/en active Active
- 2015-04-02 US US15/300,907 patent/US20170022201A1/en not_active Abandoned
- 2015-04-02 KR KR1020167028761A patent/KR102390274B1/ko not_active Expired - Fee Related
- 2015-04-02 MX MX2016012994A patent/MX369799B/es active IP Right Grant
-
2016
- 2016-09-25 IL IL248001A patent/IL248001B/en active IP Right Grant
- 2016-09-30 ZA ZA2016/06768A patent/ZA201606768B/en unknown
- 2016-09-30 CL CL2016002495A patent/CL2016002495A1/es unknown
- 2016-10-03 PH PH12016501962A patent/PH12016501962B1/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009112439A1 (en) * | 2008-03-10 | 2009-09-17 | Janssen Pharmaceutica Nv | 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017509685A (ja) | 2017-04-06 |
| SG11201608241UA (en) | 2016-10-28 |
| ES2665797T3 (es) | 2018-04-27 |
| BR112016022700B1 (pt) | 2022-01-11 |
| PE20161365A1 (es) | 2016-12-17 |
| JP6420362B2 (ja) | 2018-11-07 |
| MY185500A (en) | 2021-05-19 |
| PH12016501962A1 (en) | 2017-01-09 |
| EP3126365B1 (en) | 2018-01-10 |
| KR102390274B1 (ko) | 2022-04-22 |
| MX2016012994A (es) | 2016-12-07 |
| AU2015239100A1 (en) | 2016-09-29 |
| MX369799B (es) | 2019-11-21 |
| EA201692000A1 (ru) | 2017-01-30 |
| IL248001B (en) | 2018-11-29 |
| CA2942751A1 (en) | 2015-10-08 |
| US20170022201A1 (en) | 2017-01-26 |
| CA2942751C (en) | 2023-03-21 |
| BR112016022700A2 (enExample) | 2017-08-15 |
| MA39823A (fr) | 2018-01-09 |
| UA118120C2 (uk) | 2018-11-26 |
| CN106132964B (zh) | 2019-07-19 |
| ZA201606768B (en) | 2018-11-28 |
| NZ725406A (en) | 2022-08-26 |
| EA029758B1 (ru) | 2018-05-31 |
| KR20160140739A (ko) | 2016-12-07 |
| EP3126365A1 (en) | 2017-02-08 |
| PH12016501962B1 (en) | 2017-01-09 |
| KR102390274B9 (ko) | 2023-03-03 |
| WO2015150557A1 (en) | 2015-10-08 |
| CL2016002495A1 (es) | 2017-02-24 |
| CN106132964A (zh) | 2016-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015239100B2 (en) | Macrocylic pyridine derivatives | |
| AU2015239098B2 (en) | Macrocylic pyrimidine derivatives | |
| EP3472147B1 (en) | Azabenzimidazole derivatives as pi3k beta inhibitors | |
| CA2941206C (en) | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1h-imidazo[1,2-b]pyrazole derivatives as ros1 inhibitors | |
| AU2017338269A1 (en) | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors | |
| EP3233839B1 (en) | Heterocyclyl linked imidazopyridazine derivatives as pi3kbeta inhibitors | |
| US11130751B2 (en) | Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |